Categories: Business

(esketamine) approved in the United States as the first and only monotherapy for adults with treatment-resistant depression – Johnson & Johnson

(esketamine) approved in the United States as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson
FDA approves Johnson & Johnson nasal spray for depression as a stand-alone treatment CNBC
FDA Allows Standalone Use of Antidepressant Nasal Spray Spravato (Esketamine): Shots – Health News NPR
SPRAVATO® (esketamine) approved in the United States as first and only monotherapy for adults with treatment-resistant depression PR newswire
Johnson & Johnson’s Spravato Receives FDA Approval for Use as Monotherapy FiercePharma

remon Buul

Published by

remon Buul

3 hours ago

A slight increase in weight loss could be hiding in your glass of water: ScienceAlert

Replacing still water with sparkling water could help with weight loss alongside other steps, according…

1 minute ago

Many Reddit users are boycotting social media site X, formerly known as Twitter, after Elon…

2 minutes ago

Police said a 17-year-old student in the southern city of Nashville opened fire in a…

3 minutes ago

(Bloomberg) -- Oil edged lower after an industry report highlighted the first increase in U.S.…

4 minutes ago

The James Beard Foundation announced the semifinalists for its 2025 Restaurant and Chef Awards on…

11 minutes ago

CINCINNATI — The Cincinnati Bengals may have found a successor to former defensive coordinator Lou…

11 minutes ago